Fig. 3From: High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatinProgression-free survival (3a) and overall survival (3b) according to PLR. a: P = 0.005, b: P < 0.001 (log-rank test)Back to article page